219540-76-8

Usage

Uses

Used in Pharmaceutical Industry:
Piperid-4-yl(thien-2-yl)methanone hydrochloride is used as a potential active pharmaceutical ingredient for the development of new drugs. Its unique structure may offer novel therapeutic properties, making it a candidate for further research and development in medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, Piperid-4-yl(thien-2-yl)methanone hydrochloride serves as a key intermediate or building block in the synthesis of more complex organic molecules. Its structural features can be leveraged to create a variety of compounds with specific applications in different industries.
Used in Research and Development:
As a subject of ongoing research, Piperid-4-yl(thien-2-yl)methanone hydrochloride is utilized in academic and industrial laboratories to explore its chemical properties, reactivity, and potential applications. This includes studies aimed at understanding its interactions with biological systems and its role in the synthesis of new compounds.

InChI:InChI=1/C10H13NOS.ClH/c12-10(9-2-1-7-13-9)8-3-5-11-6-4-8;/h1-2,7-8,11H,3-6H2;1H

Upstream product

• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 1219922-46-9 1-benzoyl-4-(thien-2-yl)carbonylpiperidine 

Relevant academic research and scientific papers

Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes

The discovery of a novel series of β-methyltryptophan (β MeTrp) derivatives as selective and orally active non-peptide somatostatin receptor 2 (SSTR2) agonists for the treatment of Type 2 diabetes is described. In our previous research, Compound A, β-MeTr

Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter

To identify selective high-affinity inhibitors of the vesicular acetylcholine transporter (VAChT), we have interposed a carbonyl group between the phenyl and piperidyl groups of the prototypical VAChT ligand vesamicol and its more potent analogues benzovesamicol and 5-aminobenzovesamicol. Of 33 compounds synthesized and tested, 6 display very high affinity for VAChT (K i, 0.25-0.66 nM) and greater than 500-fold selectivity for VAChT over σ1 and σ2 receptors. Twelve compounds have high affinity (Ki, 1.0-10 nM) and good selectivity for VAChT. Furthermore, 3 halogenated compounds, namely, trans-3-[4-(4-fluorobenzoyl) piperidinyl]-2-hydroxy-1,2,3,4-tetrahydronaphthalene (28b) (Ki = 2.7 nM, VAChT/sigma selectivity index = 70), trans-3-[4-(5-iodothienylcarbonyl) piperidinyl]-2-hydroxy-1,2,3,4-tetrahydronaphthalene (28h) (Ki = 0.66 nM, VAChT/sigma selectivity index = 294), and 5-amino-3-[4-(p-fluorobenzoyl) piperidinyl]-2-hydroxy-1,2,3,4,-tetrahydronaphthalene (30b) (Ki = 2.40 nM, VAChT/sigma selectivity index = 410) display moderate to high selectivity for VAChT. These three compounds can be synthesized with the corresponding radioisotopes so as to serve as PET/SPECT probes for imaging the VAChT in vivo.

Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors

The present invention relates to compounds of the general formula as dual modulators of the 5-HT2a and D3 receptors useful against CNS disorders, wherein A, R1, R2, n, p, q and r are as defined in the specificat